Simcyp, now part of Certara, is pleased to announce the release of Version 12 of its Population-based Simulator, the pharmaceutical industry’s most sophisticated ...
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for ...
Simcyp Limited announces that it has released the latest version of its flagship simulator, further cementing its position as the industry leader in modelling and simulation of drug-drug interactions ...
(RTTNews) - Certara, Inc. (CERT),on Tuesday announced the release of Simcyp Simulator Version 24, enhancing physiologically-based pharmacokinetic or PBPK modeling to support drug development and ...
Certara, Inc., the global leader in biosimulation, today announced the release of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator platform. Simcyp PBPK Simulator ...
Simcyp Limited, the leader in the simulation and prediction of clinical drug-drug interactions, has expanded the capabilities of its world-class Population-based ADME Simulator. Version 9.0 was ...
Updates strengthen Certara's position as a leader of PBPK modeling in drug development to advance regulatory decision-making RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback